Objective Despite recent advances in endoscopic treatment and laparoscopic surgery for gastric cancers, an increase in the uptake of these therapeutic approaches has not yet been fully demonstrated.
Introduction
Gastric cancer is one of the most common cancers in Japan. Although the mortality and incidence of gastric cancers has decreased in recent years, gastric cancer remains the second most common cancer-related cause of death in Japa-nese men and third in Japanese women (1) . Photofluorography has been recommended for gastric cancer screening based on the results of several Japanese case-control and cohort studies (2, 3) . Since 1983, under the Health Service Law for the Aged, gastric cancer screening by photofluorography has been conducted nationwide for all residents aged 40 years and over (4) . Endoscopic mucosal resection (EMR) for early gastric cancers without any risk of lymph node metastasis was developed in Japan in the 1980s (5) (6) (7) . More recently, endoscopic submucosal dissection (ESD) has become accepted for the treatment of gastric cancer because of its improved curative outcome compared with EMR (8) (9) (10) (11) . ESD was accepted by the public health insurance program in Japan in 2006.
Laparoscopic gastrectomy for gastric cancers has been carried out in Japan since 1994 (12) and it was included in the public health insurance program in 2002. In recent years, the use of this therapeutic approach has rapidly increased in Japan (13) . Robot-assisted distal gastrectomy is also a promising new procedure for gastric cancer treatment that is currently being evaluated for its safety and feasibility (14, 15) .
Despite the presence of a number of reports indicating trends in the detection and treatment of gastric cancer (16, 17) , no comprehensive study into the changes in therapeutic approaches regarding treatment in Japan have so far been undertaken. The aim of this study was to investigate the trends in gastric cancer detection and the use of different therapeutic approaches in the treatment of gastric cancers detected by X-ray screening performed in 311,074 people Saga Prefecture between April 2002 and March 2011.
Materials and Methods

Subjects and study design
This study investigated the changes in the therapeutic approach in people who were diagnosed with gastric cancer through primary X-ray screening for gastric cancer at the Association of General Health of Saga. The nine-year period from April 2002 through March 2011 was established as the observation period. Laparoscopic gastrectomy was accepted for the public health insurance in 2002, and ESD was accepted for the public health insurance in 2006. The observation period was divided into three periods in a time dependent manner.
During this period, the population of Saga decreased slightly from 871,884 to 846,922. The number of subjects over 40 years of age who underwent the screening test during regional and/or workplace screening ranged from 27,444-42,791 per year. X-ray screening was performed on a total number of 311,074 subjects.
X-ray screening involved taking at least seven pictures after the ingestion of barium, with follow-up pictures taken if gastric cancer was suspected by the radiological technologist. To check these pictures, 15 groups of medical doctors (45 doctors in total) participated in this study. Each series of pictures was checked by 2 of the 15 groups. A final diagnosis of gastric cancer was confirmed by detailed endoscopic examination. In total, 534 subjects were diagnosed with gastric cancer. As indicated in Fig. 1, 18 subjects among the 534 subjects were excluded from the present study because details of the precise therapeutic approach were not available. After resection of the gastric cancer, histological examinations were carried out on all samples and 22 further subjects were excluded because the characteristics of the gastric cancer were not clear: an unclear location in 4 subjects; an unclear depth of cancer invasion in 17 subjects; and an unclear histology in 7 subjects (six subjects fell into more than one of these categories). To evaluate the changes in the therapeutic approach over time, the observation period 
Statistical analysis
All analyses were performed using the SAS statistical software package (Ver. 9.3 for Windows; SAS Institute, Cary, USA). A p value of less than 0.05 was considered statistically significant. To compare the characteristics of the cases according to the period, we used the Kruskal-Wallis test for continuous variables and χ 2 tests for categorical variables. To clarify the effect of period on decision of therapeutic approach, odds ratios (OR) and 95% confidence intervals (CIs) for endoscopic therapy or laparoscopic therapy were estimated using logistic regression models adjusted for any potential confounders (age, depth of invasion, histological type, and location).
Results
Primary X-ray screening for gastric cancer at the Association of General Health of Saga between 2002 and 2011 identified 14.3±1.7% of all screening subjects for follow-up testing due to suspected gastric cancer. Among the subjects where gastric cancer was suspected, 85.2±3.3% underwent detailed endoscopic examination and the detection rate of confirmed gastric cancer was 17.1±3.5 per 10,000 persons. Gastric cancer was diagnosed in 534 subjects out of 311,074 subjects included in the series of X-ray screening. As indicated in Table 1 , the detection rate of gastric cancer in each period was as follows: Period I: 215 patients (149 men) from 125,694 screening subjects (17.2/10,000); Period II: 158 (119 men) from 98,886 (16.0/10,000); Period III: 161 (118 men) from 86,514 (18.6/10,000). Table 2 shows the demographic data for the patients with gastric cancer in each period. Among the 534 gastric cancer patients, 18 subjects were excluded because details of the therapeutic approach could not be clearly obtained. In the remaining 516 cases, the ratio of early gastric cancer (m: mucosal cancer + sm: submucosal cancer) to advanced gastric cancer was not different for the three test periods. The ratio of early gastric cancer compared with advanced cancer tended to be high in the subjects who underwent X-ray screening every year, compared with those who were not screened every year (224/66 vs. 148/65), but the difference was not significant. The distribution of tumor location and pathological examination were also not different during the three test periods. Fig. 2 shows the proportion of patients that underwent different therapeutic approaches for gastric cancer treatment in each period. These results clearly show a time-dependent change in the prevalence of the use of different therapeutic approaches, with a decrease in open laparotomy, and an increase in laparoscopic surgery (LS) and endoscopic treatment (ET), including EMR and ESD.
To evaluate the increase in endoscopic and laparoscopic surgery, univariate and multivariate analyses were performed. Twenty-two patients were excluded from this analysis because the characteristics of their gastric cancers were not clear as indicated in Fig. 1 . The results of the univariate and multivariate analyses of ET for the gastric cancer are shown in Table 3 . ET for gastric cancer significantly increased in Period III compared with Period I according to a univariate analysis [crude odds ratio (OR) =1.94]. The increase was significant after adjusting for such factors including age, tumor characteristics, depth of invasion, histology, and tumor location according to a multivariate analysis (adjusted OR=2.49). Most of the gastric cancers treated with endoscopy were intramucosal differentiated adenocarcinomas. Table 4 shows the results of univariate and multivariate analyses of LS for the gastric cancer. A dramatic increase in laparoscopic surgery (Crude OR=15.31) was observed in Period III compared with Period I according to a univariate analysis. The increase in LS was significant after adjusting for the findings of a multivariate analysis (adjusted OR= 18.36). A multivariate analysis demonstrated that the tumor characteristics had no influence on whether or not LS was employed.
Discussion
This study shows that the use of ET and LS for gastric cancers increased significantly over the time period studied, whereas the ratio of gastric cancers that were early stage compared with advanced stage did not change during the three test periods of gastric cancer screening in Saga Prefecture, Japan. The screening system in Saga might thus have reached a plateau level regarding the detection of the gastric cancer, while previous studies indicated that the ratio of early gastric cancer detected by X-ray screening gradually increased (2, 18, 19) .
ESD is recommended according to the Japanese Gastric Cancer Treatment Guidelines for the treatment of intramucosal cancer, differentiated adenocarcinoma without ulcer, and gastric tumors measuring less than 2 cm in size, affording to a feasible and effective method for treating early gastric cancers (20) . ESD may carry an increased risk of failing to detect lymph node metastasis, therefore the expanded application of ESD is now under examination (21, 22) . ET for gastric cancers is less invasive than other therapeutic approaches, thus leading to the marked increase in ET observed in Period III compared with Period I, despite the technical difficulties and serious complications associated with ET (23-27). In the Japanese Gastric Cancer Guidelines of the 2010 edition, LS for the gastric cancer is recommended as the optimal treatment to be carried out for early stage (stage I) gastric cancer (13, 28) . This treatment is less invasive than conventional open gastrectomy, thereby minimizing the de-gree of surgical insult and maximizing the quality of life (29, 30) . LS for gastric cancer was initially introduced to replace distal gastrectomy, whereas there was no difference regarding the location of the gastric cancer treated with LS in the present study. In a revised 2010 version of the Japanese Gastric Cancer Treatment Guidelines, laparoscopyassisted gastrectomy remained classified as an investigational procedure eligible for stage IA and IB gastric cancers (13) . Several studies indicated the morbidity and mortality between laparoscopic gastrectomy and open gastrectomy to not be substantially different (31, 32) . Laparoscopyassisted distal gastrectomy should be performed by a credentialed surgeon to prevent any incidence of anastomotic leakage or pancreatic fistula formation (33) . Despite these potential complications associated with LS, its application for gastric cancers increased markedly over the period of our study. The increase in this number was partly explained by the report that laparoscopic total gastrectomy and laparoscopic proximal gastrectomy were performed in a certain percentage of gastrostomies (13) . In fact, the present study reported the use of LS for 77 gastric cancer patients out of a total of 516:21 with early gastric cancer (m) with differentiated type; 14 with early gastric cancer (m) with undifferentiated type; 26 with early gastric cancer (sm); and 16 with advanced gastric cancer. These results suggest that LS is therefore expected to be applied for various ranges and types of the gastric cancer in the near future.
The present study clearly indicated that ET and LS were applied more frequently in a time dependent manner for the patients with gastric cancer detected by the cancer screening in Japan while there was simultaneously a decrease in the best supportive care and chemotherapy for advanced gastric cancer. This retrospective study is associated with several clinical limitations including the efficacy of the X-ray devices, homogeneity in the ability to perform image reading, limitations in the surveyed area in Japan, and also the fact that this study focused only on screened subjects who were basically asymptomatic with earlier stage of the gastric cancer in Japan (34) .
In conclusion, this study clearly demonstrates that ET and LS has largely replaced open laparotomy during the period from April 2002 to March 2011 in Saga Prefecture, Japan regarding the therapeutic approach to gastric cancers, although the tumor characteristics of gastric cancers detected during the cancer screening did not show any substantial changes.
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